Skip to main content
Image coming soon

GEN6239 Therapeutic Platform Prioritization for Chief Scientific Officers

$199.00
Adding to cart… The item has been added

The Executive Diagnostic and Governance Toolkit

Therapeutic Platform Prioritization for Chief Scientific Officers

Score your own function red, amber or green, find out which part is weakest, and walk into the next budget round able to defend what you want to fix. Built for leaders reviewing decide which therapeutic platforms to prioritize for clinical translation this year.

$199 one-time
30-day money-back guarantee Verified against latest insights, updated access provided within 24h

Each order is checked and updated against the latest insights before delivery. That is why access takes up to 24 hours rather than being instant.

What you walk out with
A scored, ranked picture of your own function, and a defensible answer to what to fix first.
1 You stop guessing where you stand.
You finish with a score, not an opinion: every part of your function rated red, amber or green, with the weakest ranked first. Evidence: a Quick Scan for the shape of it, then seven domain assessments of 30 scored questions each, 210 in all, rolled into one scorecard, plus a maturity radar and a current-versus-target gap analysis.
2 You can defend the decision.
You walk into the budget round with the gap named, the owner named and done defined, instead of a case built on instinct. Evidence: project charter, scope statement, RACI, requirements traceability and work breakdown structure, pre-filled in your domain's language.
3 The work actually moves.
The month after the decision is already built, so nothing stalls waiting for someone to design a form. Evidence: more than 60 project templates across all five PMBOK process groups, plus runbooks, SOPs, a KPI framework, audit checklists and a risk matrix. 55 to 65 files in total.
4 You use it the day it lands.
No blank templates to interpret. Every workbook opens with what it is, who uses it, when, how, a 1 to 5 scoring guide, what good looks like, and a worked example you delete and type over.
The Quick Scan is one sitting. You will know your weakest area before the day is out.
Nothing in it is generic project management: the build rejects any file that could belong to another course. Updated after you enrol, so it reflects where the work stands now. The 144-chapter course is included behind it, for the parts you want to go deeper on.
Every platform decision you make now shapes the next decade of pipeline value.

The situation this is built for

You inherit complex data from discovery teams, face competing internal priorities, and must justify high-stakes platform bets without definitive clinical proof. The pressure to deliver transformative therapies clashes with incomplete datasets, uncertain mechanistic validation, and misaligned incentives across functions. Without a rigorous, shared framework, platform decisions become political, delayed, or reversed—wasting years and tens of millions.

Who this is for

Chief Scientific Officer in a biotechnology company leading therapeutic platform strategy and early clinical translation decisions. Responsible for integrating discovery insights, preclinical evidence, and clinical feasibility into a coherent platform portfolio. Regularly chairs or informs target nomination committees, platform steering boards, and R&D strategy reviews.

Who this is not for

This is not for lab scientists, clinical operations leads, or business development executives. It is not about licensing deals, market sizing, or regulatory strategy. It is specifically for science leaders accountable for platform-level go/no-go decisions.

What you walk away with

  • A standardized framework to assess platform potential across therapeutic areas
  • Clarity on which platforms to advance, deprioritize, or terminate
  • Improved alignment between discovery, translational medicine, and clinical development
  • Evidence-based decision memos for platform steering committees
  • A defensible, auditable process for portfolio governance

How this maps to your situation

  • Unclear platform definitions lead to misaligned expectations
  • Inconsistent evaluation criteria result in biased decisions
  • Lack of cross-functional integration delays platform decisions
  • Absence of governance creates portfolio drift over time

Before vs. after

Before
Platform decisions are reactive, inconsistently documented, and vulnerable to individual influence.
After
Platform assessments follow a rigorous, transparent process that produces defensible, consensus-driven outcomes.

What's included with your purchase

  • 12 modules with 12 chapters each (144 chapters)
  • Downloadable templates and worked examples for every module
  • Hand-built implementation playbook delivered alongside course access
  • 30-day money-back guarantee

Delivery and format

  • Course and learning environment access provisioned within 24 hours of purchase
  • Hand-built implementation playbook delivered alongside course access

Format: Text-based modules and chapters in the Art of Service learning environment, plus downloadable templates and worked examples for every chapter, plus the hand-built implementation playbook delivered alongside course access.

Time investment: Approximately 45 hours of focused engagement, designed to be completed in parallel with ongoing platform reviews.

If nothing changes
Without a formalized approach, platform decisions remain vulnerable to bias, groupthink, and incomplete evidence integration—leading to costly missteps, delayed pipelines, and erosion of stakeholder trust.

How this compares to the alternatives

Unlike generic strategy frameworks or academic reviews, this course delivers field-specific tools used in actual platform steering committees, with templates modeled on real R&D governance artifacts.

Also included: the full course, for when you want the reasoning behind a finding (12 modules, 144 chapters)

Depth reference. The diagnostic and the templates stand on their own; this is what to read when you want the reasoning behind a finding.

Module 1. Defining Therapeutic Platform Scope and Boundaries
Establish clear definitions for what constitutes a platform versus a program, and how to delineate its scientific and operational footprint.
12 chapters in this module
  1. Distinguishing platform from program in biologic discovery
  2. Mapping platform scope across modalities and targets
  3. Setting boundaries for platform-specific data sharing
  4. Identifying platform-enabling technologies and tools
  5. Documenting platform-specific assay development paths
  6. Clarifying platform ownership across research teams
  7. Defining platform lifecycle stages without phase language
  8. Aligning platform scope with organizational structure
  9. Tracking platform evolution over time
  10. Integrating platform definitions into R&D documentation
  11. Using platform scope to guide resource allocation
  12. Avoiding scope creep in early-stage platform development
Module 2. Assessing Platform Differentiation and Novelty
Evaluate the scientific and mechanistic uniqueness of a platform relative to existing approaches and public knowledge.
12 chapters in this module
  1. Benchmarking platform mechanisms against published literature
  2. Evaluating target engagement claims for novelty
  3. Assessing functional domain innovation in protein design
  4. Comparing platform output to endogenous biology
  5. Identifying platform-specific pharmacodynamic signatures
  6. Mapping platform advantages across tissue types
  7. Determining platform specificity in polypharmacology contexts
  8. Evaluating platform durability in chronic disease models
  9. Assessing resistance mechanisms unique to the platform
  10. Differentiating platform effects from background noise
  11. Quantifying platform signal amplification over baseline
  12. Using competitive intelligence to stress-test novelty
Module 3. Evaluating Preclinical Validation Rigor
Apply consistent standards to assess the quality, reproducibility, and relevance of preclinical data supporting platform advancement.
12 chapters in this module
  1. Designing platform-specific in vitro validation cascades
  2. Selecting appropriate cell-based models for platform testing
  3. Evaluating platform performance in primary human cells
  4. Assessing platform stability under physiological conditions
  5. Validating platform delivery and biodistribution profiles
  6. Measuring platform persistence in relevant tissues
  7. Quantifying on-target versus off-target activity
  8. Testing platform function across donor variability
  9. Assessing platform immunogenicity in humanized models
  10. Documenting assay conditions for cross-platform comparison
  11. Ensuring preclinical models reflect human disease biology
  12. Avoiding overinterpretation of surrogate endpoints
Module 4. Integrating Multidimensional Evidence Streams
Synthesize data from discovery, pharmacology, toxicology, and manufacturability into a unified platform assessment.
12 chapters in this module
  1. Aligning data timelines across functional groups
  2. Creating cross-functional evidence dashboards
  3. Weighting evidence by predictive value for translation
  4. Resolving contradictions between in vitro and in vivo results
  5. Incorporating biomarker feasibility into platform scoring
  6. Evaluating platform compatibility with existing CMC processes
  7. Assessing platform scalability from milligram to kilogram
  8. Factoring in formulation constraints early in evaluation
  9. Mapping platform-related toxicities across species
  10. Integrating biodistribution data into safety projections
  11. Using pharmacokinetic modeling to inform platform design
  12. Balancing potency with exposure in platform optimization
Module 5. Building Platform Risk Profiles
Systematically identify and categorize technical, biological, and operational risks associated with platform development.
12 chapters in this module
  1. Cataloging platform-specific failure modes in development
  2. Identifying dependency risks in reagent supply chains
  3. Assessing platform sensitivity to manufacturing variation
  4. Evaluating platform robustness across dose ranges
  5. Mapping platform-related immunogenicity concerns
  6. Predicting platform clearance mechanisms in humans
  7. Assessing platform interference with concomitant therapies
  8. Evaluating platform performance in comorbid models
  9. Documenting platform-specific assay drift risks
  10. Identifying platform bottlenecks in scale-up processes
  11. Anticipating platform-specific storage and handling issues
  12. Tracking platform mutation or degradation over time
Module 6. Designing Platform-Specific Go/No-Go Criteria
Define measurable, objective thresholds that determine whether a platform advances, requires optimization, or is terminated.
12 chapters in this module
  1. Setting minimum potency thresholds for platform progression
  2. Defining acceptable off-target activity limits
  3. Establishing platform expression duration benchmarks
  4. Creating biodistribution success criteria by tissue
  5. Setting platform-specific safety margins from toxicology
  6. Defining platform manufacturability pass/fail standards
  7. Establishing formulation stability acceptance ranges
  8. Creating platform-specific biomarker response targets
  9. Setting minimum durability requirements in disease models
  10. Defining platform-specific dosing frequency goals
  11. Establishing platform scalability milestones
  12. Creating decision rules for platform iteration cycles
Module 7. Aligning Platform Strategy with Clinical Feasibility
Evaluate whether platform characteristics enable viable clinical development paths and patient access strategies.
12 chapters in this module
  1. Assessing platform compatibility with clinical monitoring tools
  2. Evaluating platform dosing regimen practicality
  3. Mapping platform requirements to clinical site capabilities
  4. Assessing platform cold chain needs for global trials
  5. Evaluating platform administration burden on patients
  6. Aligning platform kinetics with disease progression rates
  7. Assessing platform compatibility with combination regimens
  8. Evaluating platform safety monitoring requirements
  9. Mapping platform elimination pathways for patient safety
  10. Assessing platform interactions with common medications
  11. Evaluating platform suitability for pediatric populations
  12. Considering platform implications for healthcare systems
Module 8. Facilitating Cross-Functional Platform Reviews
Lead structured discussions that integrate diverse perspectives and drive consensus on platform direction.
12 chapters in this module
  1. Structuring agenda for platform evaluation meetings
  2. Preparing decision-ready dossiers for review committees
  3. Presenting platform data with balanced risk communication
  4. Facilitating debate between discovery and development teams
  5. Incorporating regulatory insights into platform assessment
  6. Engaging manufacturing experts in early platform reviews
  7. Integrating clinical operations feedback on platform design
  8. Managing cognitive biases in group decision-making
  9. Documenting platform review outcomes and action items
  10. Creating decision trails for future audit purposes
  11. Following up on platform-related action items systematically
  12. Adjusting platform criteria based on review feedback
Module 9. Creating Platform Assessment Scorecards
Develop standardized tools to compare platforms objectively and track performance over time.
12 chapters in this module
  1. Defining core metrics for platform comparison
  2. Weighting scorecard categories by strategic importance
  3. Normalizing data across different platform types
  4. Creating visual scorecard dashboards for leadership
  5. Incorporating risk-adjusted scoring methodologies
  6. Updating scorecards with new experimental data
  7. Using scorecards to identify platform optimization needs
  8. Benchmarking platform scores against historical programs
  9. Calibrating scorecard thresholds across therapeutic areas
  10. Training teams on consistent scorecard application
  11. Auditing scorecard decisions for bias and drift
  12. Archiving scorecards for portfolio trend analysis
Module 10. Communicating Platform Rationale to Stakeholders
Articulate platform decisions clearly to executives, board members, and external partners.
12 chapters in this module
  1. Translating platform science for non-scientific audiences
  2. Creating executive summaries of platform assessments
  3. Visualizing platform data for board-level presentations
  4. Communicating platform risks without technical jargon
  5. Justifying platform termination decisions transparently
  6. Explaining platform trade-offs in resource allocation
  7. Presenting platform portfolio balance to investors
  8. Aligning platform messaging across functions
  9. Preparing platform Q&A for due diligence scenarios
  10. Documenting platform decision rationale for audits
  11. Maintaining platform communication consistency over time
  12. Anticipating stakeholder questions about platform bets
Module 11. Optimizing Platform Portfolios for Strategic Fit
Balance platform investments across risk, therapeutic area, and resource capacity to build a resilient pipeline.
12 chapters in this module
  1. Assessing platform alignment with corporate strategy
  2. Evaluating platform fit within existing therapeutic focus
  3. Balancing platform novelty against development risk
  4. Mapping platform resource demands across the portfolio
  5. Assessing platform synergy with existing assets
  6. Evaluating platform potential for repurposing paths
  7. Identifying platform gaps in therapeutic coverage
  8. Prioritizing platforms based on unmet medical need
  9. Balancing platform bets across time horizons
  10. Assessing platform compatibility with partnership models
  11. Evaluating platform exit potential from strategic view
  12. Adjusting portfolio mix based on platform performance
Module 12. Implementing Platform Governance Processes
Establish formal review cycles, decision authorities, and documentation standards for ongoing platform management.
12 chapters in this module
  1. Defining roles in platform decision-making hierarchy
  2. Scheduling regular platform portfolio reviews
  3. Creating platform stage-gate decision templates
  4. Documenting platform decisions in central repository
  5. Establishing platform data access protocols
  6. Setting platform reporting requirements for teams
  7. Creating platform archive and retrieval procedures
  8. Implementing platform knowledge transfer protocols
  9. Auditing platform governance process effectiveness
  10. Updating platform criteria based on portfolio experience
  11. Training new leaders on platform governance standards
  12. Evolving platform governance with organizational growth

Frequently asked

Is this course about choosing between specific therapeutic modalities?
No. It is about creating a repeatable evaluation system for comparing platforms regardless of modality, based on scientific rigor and strategic fit.
How is the course structured?
12 modules, each containing 12 chapters (144 chapters total).
Will this help me justify terminating a platform?
Yes. You will learn how to build evidence-based dossiers that support termination decisions and maintain team alignment.
What formats do the templates come in?
The implementation playbook downloads as PDF and editable XLSX. The course reads in your learning environment and exports to PDF for offline use. The files are yours to keep.
Can I share this with my team?
The licence is per person. Team pricing opens from three seats: reply to the order confirmation with TEAM and we will set it up.
How quickly can I start?
The diagnostic is one sitting and the templates work straight out of the kit. Account access takes up to 24 hours rather than being instant, because every order is checked and updated against the latest sources before it is delivered.
$199 one-time. Approximately 45 hours of focused engagement, designed to be completed in parallel with ongoing platform reviews..

Within 24 hours your account in the learning environment is provisioned and the tailored implementation playbook is delivered alongside it.

30-day money-back guarantee·Know your weakest area today·210 scored questions·Course included· Account access within 24 hours
30-day money-back guarantee, no questions asked.
Thousands of organisations have bought from The Art of Service since 2000.